- Report
- April 2025
- 175 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- December 2024
- 30 Pages
Global
From €2958EUR$3,250USD£2,512GBP
- Report
- May 2023
- 85 Pages
United States
From €5416EUR$5,950USD£4,600GBP
- Report
- March 2024
- 200 Pages
Global
From €3777EUR$4,150USD£3,208GBP
Hizentra is a brand of immune globulin therapy used to treat immune disorders. It is a subcutaneous injection that helps to replace antibodies that are missing or not functioning properly in the body. It is used to treat a variety of conditions, including primary immunodeficiency, chronic inflammatory demyelinating polyneuropathy, and Kawasaki disease. Hizentra is a safe and effective treatment option for those suffering from immune disorders.
Hizentra is part of a larger market of immune disorder drugs. This market includes a variety of treatments, such as monoclonal antibodies, immunomodulators, and other biologics. These treatments are used to treat a range of conditions, from autoimmune diseases to allergies.
The companies in the Hizentra market include CSL Behring, Grifols, Kedrion, Octapharma, and Shire. These companies are dedicated to providing safe and effective treatments for those suffering from immune disorders. Show Less Read more